CD79A and type 1 diabetes mellitus: GSEA performed on these two groups revealed that multiple immune-related functions and pathways such as eosinophil chemotaxis, eosinophil migration, IgG binding, interleukin-12 secretion, MHC class II protein complex, allograft rejection, graft-versus-host disease, the intestinal immune network for IgA production, systemic lupus erythematosus, and type I diabetes mellitus were significantly enriched in the high immunotherapy response group (Figures 11C, D).